Christoph Pittius

Christoph Pittius, Ph.D., Senior Vice President, Research Business Development at the City of Hope in Duarte, CA, is leading a team of Business Development professionals in charge of licensing early innovative assets of City of Hope’s research labs to pharma and biotech. He also leads City of Hope’s preclinical development effort that moves early assets, originating in the labs of City of Hope’s Principal Investigators, further along, the drug development pipeline to enable commercialization of novel medicines for patients.

Prior to joining the City of Hope, he was VP and Head of Transactions, AstraZeneca Business Development in Gothenburg, Sweden, where he and his team focused on negotiating global strategic in- and out-licensing deals of clinical-stage and on-the-market product opportunities as well as M&A in AstraZeneca’s core indications of interest.

Prior to AstraZeneca, Dr. Pittius was in Senior Business Development roles of increasing responsibility at Novartis Oncology, Boehringer Ingelheim, and Hoechst (now Sanofi) in the US and Germany, and earlier in his career also worked at a New York City-based Investment Bank. His original training was as a biochemist and molecular biologist, obtained at the Max-Planck Institute for Psychiatry, Munich, Germany.